253 related articles for article (PubMed ID: 29764505)
21. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract][Full Text] [Related]
22. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
[TBL] [Abstract][Full Text] [Related]
23. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC
Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191
[TBL] [Abstract][Full Text] [Related]
24. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
25. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract][Full Text] [Related]
26. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
[TBL] [Abstract][Full Text] [Related]
27. Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report.
Yang Y; He X; Xiao W; Bai J; Liu Y
Anticancer Drugs; 2024 Mar; 35(3):292-297. PubMed ID: 38179893
[TBL] [Abstract][Full Text] [Related]
28. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Du X; Shao Y; Qin HF; Tai YH; Gao HJ
Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
[TBL] [Abstract][Full Text] [Related]
29. A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
Lu Y; Fan Z; Zhu SJ; Huang X; Zhuang Z; Li Y; Deng Z; Gao L; Hong X; Zhang T; Li L; Sun X; Huang W; Zhang J; Liu Y; Zhang B; Jiang J; Gui F; Wang Z; Li Q; Song S; Huang X; Wu Q; Chen L; Zhou D; Zhang J; Yun CH; Chen L; Deng X
EMBO Mol Med; 2022 Jan; 14(1):e14296. PubMed ID: 34845836
[TBL] [Abstract][Full Text] [Related]
30. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Roper N; El Meskini R; Maity T; Atkinson D; Day A; Pate N; Cultraro CM; Pack S; Zgonc V; Weaver Ohler Z; Guha U
Cancer Res Commun; 2024 Feb; 4(2):337-348. PubMed ID: 38276867
[TBL] [Abstract][Full Text] [Related]
31. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Kauffmann-Guerrero D; Kahnert K; Huber RM
Drugs; 2021 Jan; 81(1):87-100. PubMed ID: 33226527
[TBL] [Abstract][Full Text] [Related]
32. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
Paliouras AR; Buzzetti M; Shi L; Donaldson IJ; Magee P; Sahoo S; Leong HS; Fassan M; Carter M; Di Leva G; Krebs MG; Blackhall F; Lovly CM; Garofalo M
EMBO Mol Med; 2020 Jul; 12(7):e11099. PubMed ID: 32558295
[TBL] [Abstract][Full Text] [Related]
33. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
[TBL] [Abstract][Full Text] [Related]
34. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
Mancini M; Gal H; Gaborit N; Mazzeo L; Romaniello D; Salame TM; Lindzen M; Mahlknecht G; Enuka Y; Burton DG; Roth L; Noronha A; Marrocco I; Adreka D; Altstadter RE; Bousquet E; Downward J; Maraver A; Krizhanovsky V; Yarden Y
EMBO Mol Med; 2018 Feb; 10(2):294-308. PubMed ID: 29212784
[TBL] [Abstract][Full Text] [Related]
35. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.
Chimbangu CT; Ya Z; Xi L; Jiayue Z; Xiao M; Ying W; Xingxu Y; Liu X
Anticancer Drugs; 2024 Jan; 35(1):109-115. PubMed ID: 37578745
[TBL] [Abstract][Full Text] [Related]
36. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
37. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
[TBL] [Abstract][Full Text] [Related]
38. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
[TBL] [Abstract][Full Text] [Related]
39. 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
Meraz IM; Majidi M; Fang B; Meng F; Gao L; Shao R; Song R; Li F; Lissanu Y; Chen H; Ha MJ; Wang Q; Wang J; Shpall E; Jung SY; Haderk F; Gui P; Riess JW; Olivas V; Bivona TG; Roth JA
Commun Biol; 2023 May; 6(1):509. PubMed ID: 37169941
[TBL] [Abstract][Full Text] [Related]
40. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.
Wierdl M; Tsurkan L; Chi L; Hatfield MJ; Tollemar V; Bradley C; Chen X; Qu C; Potter PM
Cancer Chemother Pharmacol; 2018 Aug; 82(2):251-263. PubMed ID: 29855693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
